on your expectations of HAE prophylaxis1

SIGNIFICANT AND SUSTAINED REDUCTIONS IN HAE ATTACKS1

Long-term reductions seen across 1 year2

See the data

At-home dosing every 4 or 8 weeks1

Recommended dosing for DAWNZERA 80 mg SC is once every 4 weeks. Every 8 weeks may also be considered

See dosing info

AN evidence-based switch WITH DAWNZERA3

The only HAE prophylactic evaluated in a dedicated clinical trial of patients who switched from other LTPs

See switch data

HAE=hereditary angioedema; LTP=long-term prophylactic treatment; SC=subcutaneous.

Ready to flip the switch?

Explore HAE impact Get patients started See the switch protocol

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

INDICATION

DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information for DAWNZERA.

References: 1. DAWNZERA. Prescribing information. Ionis Pharmaceuticals. 2. Lumry WR, Tachdjian R, Craig T, et al. Donidalorsen for long-term prophylaxis of hereditary angioedema attacks: results from the OASISplus open-label extension cohort at year 1. J Asthma Allergy. 2026;19:592079. doi:10.2147/JAA. S592079 3. Riedl MA, Bernstein JA, Jacobs JS, et al. Switching long-term prophylaxis to donidalorsen for hereditary angioedema:1-year OASISplus results. Allergy. 2026;1-10. doi:10.1111/all.70294